Related references
Note: Only part of the references are listed.CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Mohamad Hamieh et al.
NATURE (2019)
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
Hejin Jia et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Target selection for CAR-T therapy
Jianshu Wei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
Kevin Bielamowicz et al.
NEURO-ONCOLOGY (2018)
Nanobody Based Dual Specific CARs
Stijn De Munter et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Sujita Sukumaran et al.
CANCER DISCOVERY (2018)
Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
Keisuke Watanabe et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
Kai-chao Feng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
Jeannette Fischer et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Fully human CD19-specific chimeric antigen receptors for T-cell therapy
D. Sommermeyer et al.
LEUKEMIA (2017)
Therapeutic T cell engineering
Michel Sadelain et al.
NATURE (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
Giedre Krenciute et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
Astero Klampatsa et al.
CANCERS (2017)
Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity
Spencer Park et al.
SCIENTIFIC REPORTS (2017)
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Kole T. Roybal et al.
CELL (2016)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells (vol 44, pg 380, 2016)
Omkar U. Kawalekar et al.
IMMUNITY (2016)
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)
Meenakshi Hegde et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Hanren Dai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases
Mark J. Osborn et al.
MOLECULAR THERAPY (2016)
An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells
Yajing Zhang et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Hanren Dai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
Eugenia Zah et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Christine E. Brown et al.
CLINICAL CANCER RESEARCH (2015)
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz et al.
CLINICAL CANCER RESEARCH (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo et al.
CANCER DISCOVERY (2015)
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells
Michael C. Jensen et al.
IMMUNOLOGICAL REVIEWS (2014)
Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas
Ian F. Pollack et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Liang-Chuan S. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Nanobodies: Natural Single-Domain Antibodies
Serge Muyldermans
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 82 (2013)
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
Eric Tran et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
Meenakshi Hegde et al.
MOLECULAR THERAPY (2013)
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Sunitha Kakarla et al.
MOLECULAR THERAPY (2013)
PD-1-and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Victor D. Fedorov et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Evripidis Lanitis et al.
CANCER IMMUNOLOGY RESEARCH (2013)
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Zakaria Grada et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Genetic engineering of T cells for adoptive immunotherapy
Angel Varela-Rohena et al.
IMMUNOLOGIC RESEARCH (2008)
T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity
M Chmielewski et al.
JOURNAL OF IMMUNOLOGY (2004)
A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease
G Akpek et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2001)
Share Paper
